Form D · Other Technology
Capra Biosciences, Inc.
Manassas, VA · CIK 0001902373
Offering snapshot reported Oct 1, 2024 · SEC filing
- Reported sold
- $500K Offering amount: $1.5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 16, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 1, 2024 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Dec 12, 2023 | Initial | $3,400,000 | No comparison | 9 | SEC filing |
| Jan 4, 2022 | Initial | $50,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-525535
Simple Agreement for Future Equity
Source: Form D, filed Oct 1, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Douglas Cameron | Director |
| Danielle Joseph | Director |
| Andrew Magyar | Director, Executive |
| Elizabeth Onderko | Director, Executive, Promoter |
| Pae Wu | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
11100 Endeavor Ct Unit 149
Manassas, VA, 20109
Manassas, VA, 20109